NCT01326845View on ClinicalTrials.gov

Myelodysplastic Syndrome (MDS) Gastrointestinal (GI) Tolerability Study

PHASE4TerminatedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

September 30, 2012

Study Completion Date

September 30, 2012

Conditions
Myelodysplastic SyndromeTransfusional Iron Overload
Interventions
DRUG

Deferasirox

Trial Locations (10)

901

Novartis Investigative Site, Bloemfontein

10126

Novartis Investigative Site, Torino

14033

Novartis Investigative Site, Caen

15100

Novartis Investigative Site, Alessandria

28033

Novartis Investigative Site, Madrid

29200

Novartis Investigative Site, Brest

33604

Novartis Investigative Site, Pessac

54511

Novartis Investigative Site, Vandœuvre-lès-Nancy

87042

Novartis Investigative Site, Limoges

00133

Novartis Investigative Site, Roma

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY